4 completed, 1 active not recruiting, 1 recruiting. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 4, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Congenital Hyperinsulinism: new trials by email Literature Review of Congenital Hyperinsulinism trials Research Report on Congenital Hyperinsulinism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RZ358 Treatment for Congenital Hyperinsulinism RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC - Congenital Hyperinsulinism | Phase 3 | Active not recruiting | Rezolute | 56 | 2024-01-11 | 2026-01-08 |
| 18F-DOPA II - PET Imaging Optimization 18F-DOPA, Furosemide Injection - Congenital Hyperinsulinism, Neuroblastoma | Phase 3 | Recruiting | University of Alberta | 800 | 2021-01-20 | 2026-02-09 |
| Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism dasiglucagon, Placebo - Congenital Hyperinsulinism | Phase 2 / Phase 3 | Completed | Zealand Pharma | 12 | 2020-06-19 | 2025-03-14 |
| Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism dasiglucagon - Congenital Hyperinsulinism | Phase 3 | Completed | Zealand Pharma | 42 | 2019-05-02 | 2026-08-03 |
| A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism Dasiglucagon, Standard of Care - Congenital Hyperinsulinism | Phase 3 | Completed | Zealand Pharma | 32 | 2019-02-07 | 2023-12-13 |
| 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety 18F-DOPA - Congenital Hyperinsulinism, Neuroblastoma | Phase 3 | Completed | University of Alberta | 400 | 2017-06-29 | 2022-01-10 |
Neuroblastoma (2) · Neuroendocrine Tumors (2) · Parkinson Disease (2) · Brain Neoplasms (1) · Digestive System Diseases (1) · Glucose Metabolism Disorders (1) · Hyperinsulinism (1) · Hypoglycemia (1) · Lewy Body Disease (1) · Metabolic Diseases (1) · Pancreatic Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Infant, Newborn, Diseases (6) · Nutritional and Metabolic Diseases (6) · Digestive System Diseases (5) · Glucose Metabolism Disorders (5) · Hyperinsulinism (5) · Hypoglycemia (5) · Metabolic Diseases (5) · Pancreatic Diseases (5) · Basal Ganglia Diseases (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Movement Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
dasiglucagon (3) · Standard of Care (2) · fluorodopa F 18 (2) · 4-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid (1) · Furosemide (1)
Zealand Pharma (3) · University of Alberta (2) · Rezolute (1)
Germany (4) · United Kingdom (4) · United States (4) · Israel (3) · Canada (2) · Bulgaria (1) · Denmark (1) · France (1) · Georgia (1) · Greece (1) · Oman (1) · Qatar (1) · Spain (1) · Turkey (Türkiye) (1) · Vietnam (1)
Charlotte Teglman Schioeler (1) · Gopal Saha, MD (1) · Jelena Ivkovic, MD (1) · Jonathan Abele, MD (1) · Jonathan T Abele, MD (1)
2017 (1)